- Home
- AVPT vs MRUS Comparison
AVPT vs MRUS Comparison
Compare AVPT & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVPT
- MRUS
- Stock Information
- Founded
- AVPT 2001
- MRUS 2003
- Country
- AVPT United States
- MRUS Netherlands
- Employees
- AVPT N/A
- MRUS 260
- Industry
- AVPT Computer Software: Prepackaged Software
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- AVPT Technology
- MRUS Health Care
- Exchange
- AVPT Nasdaq
- MRUS Nasdaq
- Market Cap
- AVPT 3.9B
- MRUS 4.1B
- IPO Year
- AVPT N/A
- MRUS 2016
- Fundamental
- Price
- AVPT $17.96
- MRUS $53.11
- Analyst Decision
- AVPT Buy
- MRUS Strong Buy
- Analyst Count
- AVPT 5
- MRUS 12
- Target Price
- AVPT $17.40
- MRUS $87.92
- AVG Volume (30 Days)
- AVPT 1.3M
- MRUS 2.0M
- Earning Date
- AVPT 08-07-2025
- MRUS 07-31-2025
- Dividend Yield
- AVPT N/A
- MRUS N/A
- EPS Growth
- AVPT N/A
- MRUS N/A
- EPS
- AVPT N/A
- MRUS N/A
- Revenue
- AVPT $349,012,000.00
- MRUS $54,732,000.00
- Revenue This Year
- AVPT $23.25
- MRUS $75.57
- Revenue Next Year
- AVPT $18.07
- MRUS $31.84
- P/E Ratio
- AVPT N/A
- MRUS N/A
- Revenue Growth
- AVPT 21.70
- MRUS 42.77
- 52 Week Low
- AVPT $9.38
- MRUS $33.19
- 52 Week High
- AVPT $20.25
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- AVPT 43.75
- MRUS 53.18
- Support Level
- AVPT $18.51
- MRUS $52.41
- Resistance Level
- AVPT $19.58
- MRUS $54.59
- Average True Range (ATR)
- AVPT 0.54
- MRUS 2.15
- MACD
- AVPT -0.19
- MRUS -0.77
- Stochastic Oscillator
- AVPT 1.36
- MRUS 7.62
About AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.